UBS Warns Trump's 100% Generic Drug Tariff Puts Indian Pharma "On Notice"; Goldman Flags Reshoring WinnersZeroHedge·Jul 22 at 08:45 AMTEVA-1.19%VTRS-0.23%
J&J’s Tremfya remains on top in Q2 pharma ad spending leagueFiercepharma·Jul 21 at 08:08 AMJNJ+1.59%TEVA-1.19%
Piper Sandler Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)Tip Ranks·Jul 20 at 06:27 AMTEVA-1.19%
Cross-Sector Metrics Diverge as Stellantis Surges and Energy Micro-Caps Face RestructuringGlobal Report·Jul 19 at 04:13 AMWING+0.25%STLA-1.04%
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo StudyMarket Beat·Jul 12 at 05:02 PMTEVA-1.19%
Sumitomo Mitsui Trust Group Inc. Has $65.48 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVAMarket Beat·Jul 12 at 11:33 AMTEVA-1.19%
Equitable Trust Co. Invests $2.59 Million in Teva Pharmaceutical Industries Ltd. $TEVAMarket Beat·Jul 11 at 07:56 AMTEVA-1.19%00005-6.00%
Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilarPharmaceutical Technology·Jul 10 at 04:31 AMTEVA-1.19%
Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea® (aflibercept), in CanadaPR Newswire·Jul 9 at 07:05 AMTEVA-1.19%03121-4.56%
Teva And Polpharma Biologics Ink Global Licensing Deal For Ocrevus Biosimilarrttnews·Jul 9 at 07:52 AMTEVA-1.19%
